Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Oct 17, 2025 (12 months ago)

Acetaminophen 500mg Caffeine 65mg caplets (Pain Reliever)

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Labeling: Label Mix-up. This issue affects the outer box labeling only. The box incorrectly states the ingredients Acetaminophen 500mg and Caffeine 65mg. The inner pouch correctly states the ingredients are Aspirin (NSAID)*500mg and Caffeine 32.5mg.

Cause type: Labeling / mix-up

Wrong label, wrong strength, mixed-up products, or packaging errors. One of the most dangerous causes - you can end up taking the wrong drug or the wrong dose. All labeling / mix-up recalls.

What was recalled

Acetaminophen 500mg Caffeine 65mg caplets, packaged as 2 caplets per packet further packaged in a 50-count box, AERO TAB, Manufactured for AERO HEALTHCARE US, Valley-Cottage, NY, 10989, NDC 55305-135-01

Affected NDC 55305-0135-01

Compare with the code on your package — it is the most precise check available.

Drug: Acetaminophen Category: Pain Relief & OTC Medication

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
AeroTab Pain Reliever
Pain Reliever
NDC 55305-0135
ASPIRIN 500 mg/1; CAFFEINE 32.5 mg/1 Tablet, Film Coated
Oral
Aero Healthcare OTC
Recalling firm
Aero Healthcare
NDC code
55305-135-01
Origin
NY, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0155-2026 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other Acetaminophen recalls

See all
Class II · Moderate risk

Tylenol

Defective Container

Ongoing Packaging defect Kenvue Brands LLC D-0121-2026
Class II · Moderate risk

Acetaminophen Tablets

cGMP deviations: Due to confirmed consumer complaints received with the observation of tablet discoloration (brown surface on tablets).

Ongoing Failed specification Aurobindo Pharma USA Inc NDC 72288-405-10 D-0471-2025

Other labeling / mix-up recalls from 2025

All labeling / mix-up recalls
Class II · Moderate risk

Levothyroxine Sodium Tablets

Product Mix-Up: A single bottle of this lot was reported by a pharmacy to contain 88 mcg tablets instead of 150 mcg tablets.

Ongoing Labeling / mix-up Alvogen, Inc D-0259-2026
Class III · Low risk

parodontax

Labeling: Incorrect or Missing Lot and/or Exp Date: Potential for missing or illegible lot and expiration date coding on the bottles.

Ongoing Labeling / mix-up Haleon US Holdings LLC NDC 0135-0651-02 D-0297-2026
Class I · High risk

POTASSIUM CHLORIDE Inj.

Labeling: Label Error on Declared Strength-The overwrap label may incorrectly identify the product as POTASSIUM CHLORIDE Inj. 10 mEq instead of POTASSIUM CHLORIDE Inj. 20 mEq

Ongoing Labeling / mix-up Otsuka ICU Medical LLC NDC 0990-7074-26 D-0181-2026